BETHESDA, MD – Micromet Inc. (Nasdaq:MITI), a company developing novel, proprietary antibodies to treat cancer, inflammation and autoimmune diseases, has entered an agreement with Kingsbridge Capital Limited, which has committed up to $75 million in capital over the next three years to the Micromet.

Micromet issued a warrant to Kingsbridge to purchase up to 135,000 shares of common stock at an exercise price of $4.44 per share, which represents a 10 percent premium over the average of the closing prices of Micromet’s common stock during the five trading days immediately preceding the signing of the agreement.

Micromet has no obligation to access the facility and will have full control over the amount and the timing of any financing under the facility, subject to certain conditions outlined below.

This agreement replaces the Company’s 2006 CEFF agreement under which Kingsbridge had committed up to $25 million of capital.

The company did not raise capital under the 2006 CEFF.

the company uses its proprietary BiTE antibody platform to create a new class of antibodies that specifically activate T cells from the patient’s own immune system to eliminate cancer cells or other disease-related cells.

On the Web: www.micromet-inc.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2008, TechJournal South. All rights reserved.